Advertisement

Fibrosis in Ulcerative Colitis

  • Fernando Magro
  • Tatiana António
Chapter

Abstract

Intestinal fibrosis is a classic complication in Inflammatory Bowel Diseases where chronic inflammation and abnormal tissue repair together lead to a compromised bowel function. Although fibrosis and stricture formation are acknowledged features of Crohn’s disease courses, these complications remain poorly studied in ulcerative colitis (UC). The relevance of this topic has long been ignored, despite the well-known prevalence of stenosis in UC, its clinical impact in motility and the importance of assessing stricture malignancy.

Fibrosis in UC is now perceived as a dynamic and reversible process. However, still no proper antifibrotic therapy exist, mainly due to the very limited pathophysiological insights.

This chapter aims to review the current knowledge about fibrosis development in UC, outlining disease basic concepts, epidemiology, histopathologic features and clinical consequences.

Keywords

Ulcerative colitis Inflammatory bowel diseases Fibrosis Stenosis Myofibroblasts Extracellular matrix 

References

  1. 1.
    Geboes K. What histologic features best differentiate Crohn’s disease from ulcerative colitis? Inflamm Bowel Dis. 2008;14(Suppl 2):S168–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Whitlow CB. Ulcerative proctitis. Clin Colon Rectal Surg. 2004;17(1):21–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13(4-5):463–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23; quiz 524.CrossRefGoogle Scholar
  8. 8.
    Cosnes J, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Langan RC, et al. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76(9):1323–30.PubMedGoogle Scholar
  10. 10.
    Latella G, et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17(10):1283–304.PubMedGoogle Scholar
  11. 11.
    Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–31.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(4):235–41.Google Scholar
  13. 13.
    Johnson LA, et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β–induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014;20(1):154–65.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42; quiz e30.CrossRefGoogle Scholar
  15. 15.
    Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol. 2013;5:237–47.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Takahashi H, et al. Second peak in the distribution of age at onset of ulcerative colitis in relation to smoking cessation. J Gastroenterol Hepatol. 2014;29(8):1603–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Latella G, Rieder F. Intestinal fibrosis: ready to be reversed. Curr Opin Gastroenterol. 2017;33(4):239–45.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33(7):938–41.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Rogler G. Pathogenesis of strictures in ulcerative colitis: a field to explore. Digestion. 2011;84(1):10–1.CrossRefPubMedGoogle Scholar
  20. 20.
    Yamagata M, et al. Submucosal fibrosis and basic-fibroblast growth factor-positive neutrophils correlate with colonic stenosis in cases of ulcerative colitis. Digestion. 2011;84(1):12–21.CrossRefPubMedGoogle Scholar
  21. 21.
    Ordás I, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–19.CrossRefPubMedGoogle Scholar
  22. 22.
    Latella G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014;8(10):1147–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Spehlmann ME, et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis. 2008;14(7):968–76.CrossRefPubMedGoogle Scholar
  24. 24.
    Taurog JD, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rieder F, Fiocchi C. Intestinal fibrosis in IBD—a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6(4):228–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Ippolito C, et al. Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative colitis. J Crohns Colitis. 2016;10(10):1194–204.CrossRefPubMedGoogle Scholar
  28. 28.
    Latella G, Rieder F. Time to look underneath the surface: ulcerative colitis-associated fibrosis. J Crohns Colitis. 2015;9(11):941–2.CrossRefPubMedGoogle Scholar
  29. 29.
    de Bruyn JR, et al. Development of fibrosis in acute and longstanding ulcerative colitis. J Crohns Colitis. 2015;9(11):966–72.CrossRefPubMedGoogle Scholar
  30. 30.
    Manetti M, et al. Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitis. J Cell Mol Med. 2015;19(1):62–73.CrossRefPubMedGoogle Scholar
  31. 31.
    Maul J, Zeitz M. Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Langenbeck’s Arch Surg. 2012;397(1):1–10.CrossRefGoogle Scholar
  32. 32.
    Torres J, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18(7):1356–63.CrossRefPubMedGoogle Scholar
  33. 33.
    Gordon IO, et al. Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis. 2014;20(11):2198–206.CrossRefPubMedGoogle Scholar
  34. 34.
    Rieder F, et al. Wound healing and fibrosis in intestinal disease. Gut. 2007;56(1):130–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bettenworth D, Rieder F. Pathogenesis of intestinal fibrosis in inflammatory bowel disease and perspectives for therapeutic implication. Dig Dis. 2017;35(1-2):25–31.CrossRefPubMedGoogle Scholar
  36. 36.
    Speca S, et al. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol. 2012;18(28):3635–61.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Latella G, et al. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2015;50(1):53–65.CrossRefPubMedGoogle Scholar
  39. 39.
    Johnson LA, et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a “Top-Down” approach to intestinal fibrosis in mice. Inflamm Bowel Dis. 2012;18(3):460–71.CrossRefPubMedGoogle Scholar
  40. 40.
    Heller F, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129(2):550–64.CrossRefPubMedGoogle Scholar
  41. 41.
    Fonseca-Camarillo G, et al. Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17(10):E135–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Sponheim J, et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol. 2010;177(6):2804–15.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7(3):226–36.CrossRefPubMedGoogle Scholar
  44. 44.
    Simmons JG, et al. IGF-I and TGF-beta1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. Am J Physiol Gastrointest Liver Physiol. 2002;283(3):G809–18.CrossRefPubMedGoogle Scholar
  45. 45.
    Theiss AL, et al. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005;280(43):36099–109.CrossRefPubMedGoogle Scholar
  46. 46.
    Hormi K, Lehy T. Transforming growth factor-alpha in vivo stimulates epithelial cell proliferation in digestive tissues of suckling rats. Gut. 1996;39(4):532–8.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Kumagai S, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2001;195(1):21–33.CrossRefPubMedGoogle Scholar
  48. 48.
    Rieder F, et al. Intestinal fibrosis and liver fibrosis: consequences of chronic inflammation or independent pathophysiology? Inflamm Intest Dis. 2016;1(1):41–9.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Andoh A, et al. Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J Gastroenterol. 2002;37(Suppl 14):33–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G677–83.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease - current knowledge and future perspectives. J Crohns Colitis. 2008;2(4):279–90.CrossRefPubMedGoogle Scholar
  52. 52.
    Bainbridge P. Wound healing and the role of fibroblasts. J Wound Care. 2013;22(8):407–8, 410-12.CrossRefPubMedGoogle Scholar
  53. 53.
    Witte MB, Barbul A. General principles of wound healing. Surg Clin North Am. 1997;77(3):509–28.CrossRefPubMedGoogle Scholar
  54. 54.
    Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-β1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7(1):16–26.CrossRefPubMedGoogle Scholar
  55. 55.
    Leeb SN, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125(5):1341–54.CrossRefPubMedGoogle Scholar
  56. 56.
    Lawrance IC, et al. Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis. 2015;11(12):1491–503.PubMedCentralGoogle Scholar
  57. 57.
    Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology. 2008;47(4):1394–400.CrossRefPubMedGoogle Scholar
  58. 58.
    Sonnenberg A, Genta RM. Epithelial dysplasia and cancer in IBD strictures. J Crohns Colitis. 2015;9(9):769–75.CrossRefPubMedGoogle Scholar
  59. 59.
    Goulston SJ, McGovern VJ. The nature of benign strictures in ulcerative colitis. N Engl J Med. 1969;281(6):290–5.CrossRefPubMedGoogle Scholar
  60. 60.
    Bassotti G, et al. Gastrointestinal motility disorders in inflammatory bowel diseases. World J Gastroenterol. 2014;20(1):37–44.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol. 2007;42(Suppl 17):48–51.CrossRefPubMedGoogle Scholar
  62. 62.
    Neunlist M, et al. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut. 2003;52(1):84–90.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Vrees MD, et al. Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg. 2002;137(4):439–46.CrossRefPubMedGoogle Scholar
  64. 64.
    Choi K, et al. Impaired integrity of DNA after recovery from inflammation causes persistent dysfunction of colonic smooth muscle. Gastroenterology. 2011;141(4):1293–301, 1301.e1-3.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    La JH, et al. Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis. World J Gastroenterol. 2003;9(12):2791–5.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):340–350.e6.CrossRefPubMedGoogle Scholar
  67. 67.
    Trivedi PP, Jena GB. Role of alpha-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis. Food Chem Toxicol. 2013;59:339–55.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of MedicineUniversity of PortoPortoPortugal

Personalised recommendations